Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Print E-mail
PRNewsWire
Wednesday, 20 September 2017 07:00
The Phase 1 randomized, placebo-controlled single ascending- and repeat-dose study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PTG-300 in 62
Read more...
 
NW BIO Announces Registered Direct Offering Of $1.75 Million Print E-mail
PRNewsWire
Wednesday, 20 September 2017 07:00
In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20per share.  Additionally, the investors
Read more...
 
Rise in Teenage Opioid Deaths Highlights Desperate Need for Adolescent Drug Treatment Print E-mail
PRNewsWire
Wednesday, 20 September 2017 07:00
"The rise in teen exposure to opioids is particularly disturbing because of the vulnerability of these young people," said Mitchell S. Rosenthal, M.D., the
Read more...
 
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development Print E-mail
PRNewsWire
Wednesday, 20 September 2017 07:00
"Dr. Theeuwes' extensive experience and success in developing pharmaceuticals for both major and rare diseases is an ideal fit with DURECT's pipeline of products," stated
Read more...
 
Technical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma Print E-mail
PRNewsWire
Wednesday, 20 September 2017 05:35
If you want a Stock Review on VNDA, ACAD, ACHN, or AGIO then come over to http://dailystocktracker.com/register/and sign up for your free customized report.
Read more...
 
Edesa Biotech Completes Financing to Develop Novel Dermatology and Anorectal Treatments Print E-mail
PRNewsWire
Wednesday, 20 September 2017 05:25
Commenting on the financing, the company's founder and CEO, Dr. Par Nijhawan M.D., F.R.C.P.C, Gastroenterologist, noted "We founded this company in 2015 to address what
Read more...
 
PharmaMar débute des études cliniques avec un nouveau composé, PM14, chez des patients atteints de tumeurs solides Print E-mail
PRNewsWire
Wednesday, 20 September 2017 05:06
     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b) Après sa phase préclinique, lors de laquelle le composé a démontré son activité dans des tumeurs solides de modèles animaux, cette
Read more...
 
Soligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Print E-mail
PRNewsWire
Wednesday, 20 September 2017 05:00
"We are appreciative of the support provided by NIDCR for the previous Phase 2 clinical study and

Error. Page cannot be displayed. Please contact your service provider for more details. (19)

now for the recently initiated pivotal Phase 3
Read more...
 
PharmaMar fa partire uno studio clinico con nuovo composto -PM14- nei pazienti con tumori solidi Print E-mail
PRNewsWire
Wednesday, 20 September 2017 04:47
     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b) Dopo la fase preclinica, in cui il composto ha dimostrato la propria attività sui tumori solidi negli animali, questo studio clinico
Read more...
 
PharmaMar startet klinische Studien mit einem neuen Präparat -PM14- bei Patienten mit soliden Tumoren Print E-mail
PRNewsWire
Wednesday, 20 September 2017 04:44
     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b) Nach seiner präklinischen Phase, in der das Präparat seine Aktivität in soliden Tumoren in Tiermodellen nachgewiesen hat, besteht das Hauptziel dieser
Read more...
 
XW Labs secures over $17M Series B financing led by Elements Capital and WI Harper Print E-mail
PRNewsWire
Wednesday, 20 September 2017 04:00
"Our company is entering a critical stage where we anticipate at least 1 program to enter clinical trials per year starting in 2018" said Dr.
Read more...
 
Benchling Announces Groundbreaking Workflow & Results Management Solution to Organize, Optimize, and Measure Biologics R&D Print E-mail
PRNewsWire
Wednesday, 20 September 2017 03:00
The increasing complexity of biologics R&D has hindered the ability of organizations to make sense of their data. More than ever, biologics R&D is characterized
Read more...
 
Enterome to Move its Research Laboratories to Genopole, France's First Biocluster Print E-mail
PRNewsWire
Wednesday, 20 September 2017 02:00
About 15 of the 40 people employed by Enterome will work permanently at Genopole in laboratories dedicated to the discovery and development of innovative therapeutic
Read more...
 
Agena Bioscience anuncia: Molecular Health será el primer proveedor de software de interpretación en MassARRAY Insights™ Print E-mail
PRNewsWire
Tuesday, 19 September 2017 19:14
SAN DIEGO,, 20 de septiembre de 2017 /PRNewswire/ -- Agena Bioscience, un proveedor líder de soluciones de genética molecular, y Molecular Health, un líder
Read more...
 
Agena Bioscience annonce que Molecular Health sera le premier fournisseur de logiciels d'interprétation pour MassARRAY Insights™ Print E-mail
PRNewsWire
Tuesday, 19 September 2017 16:23
Cette relation s'inscrit dans le cadre du réseau de rapport MassARRAY Insights d'Agena Bioscience, un programme de collaboration entre Agena Bioscience et des fournisseurs de
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 1584
BMR:1